Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
S-8
Registration of securities for employees
29 Mar 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
29 Mar 23
8-K
Departure of Directors or Certain Officers
14 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
8-K
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
10 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
12 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
EFFECT
Notice of effectiveness
8 Apr 22
424B5
Prospectus supplement for primary offering
7 Apr 22
UPLOAD
Letter from SEC
6 Apr 22
CORRESP
Correspondence with SEC
5 Apr 22
S-3
Shelf registration
30 Mar 22
S-8
Registration of securities for employees
30 Mar 22
10-K
2021 FY
Annual report
30 Mar 22
8-K
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
30 Mar 22
8-K
Departure of Directors or Certain Officers
4 Mar 22
8-K
Entry into a Material Definitive Agreement
25 Jan 22
8-K
Departure of Directors or Certain Officers
16 Dec 21
Latest ownership filings
4
Grant Yonehiro
6 Mar 24
4
Edith A. Perez
6 Mar 24
4
Randall C Schatzman
6 Mar 24
4
William P. Quinn
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Vivo Capital VIII, LLC
13 Feb 24
SC 13D/A
Pivotal bioVenture Partners Fund I, L.P.
12 Feb 24
5
Grant Yonehiro
6 Feb 24
5
Edith A. Perez
6 Feb 24
5
Randall C Schatzman
6 Feb 24
4
William P. Quinn
13 Dec 23
4
EDGAR ENGLEMAN
1 Dec 23
4
EDGAR ENGLEMAN
22 Nov 23
4
Change in insider ownership
22 Nov 23
4
EDGAR ENGLEMAN
20 Nov 23
4
Change in insider ownership
20 Nov 23
4
MAHENDRA SHAH
14 Jun 23
4
NICOLE ONETTO
14 Jun 23
4
BRIAN O'CALLAGHAN
14 Jun 23
4
RICHARD A MD MILLER
14 Jun 23
4
Frank D. Lee
14 Jun 23
4
KATHLEEN LAPORTE
14 Jun 23
4
JAMES HEALY
14 Jun 23
4
EDGAR ENGLEMAN
14 Jun 23
4
Laura Berner
14 Jun 23
SC 13G
TANG CAPITAL PARTNERS LP
20 Apr 23
4
Grant Yonehiro
28 Feb 23
4
Randall C Schatzman
28 Feb 23
4
Edith A. Perez
28 Feb 23
4
William P. Quinn
28 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
5
Grant Yonehiro
7 Feb 23
5
Randall C Schatzman
7 Feb 23
5
Edith A. Perez
7 Feb 23
5
William P. Quinn
7 Feb 23
SC 13D/A
Novo Holdings A/S
4 Jan 23
SC 13D/A
Novo Holdings A/S
28 Dec 22
4
RICHARD A MD MILLER
16 Dec 22